Cameroon, one of the first African countries to fold a malaria vaccine into its routine childhood immunization program, says the shot is measurably reducing illness but that too few children complete the full course to lock in the protection [1]. The vaccine is not a single jab; it is a multi-dose schedule, and health officials in Cameroon report that final-dose coverage remains weak, meaning many children start the series and never finish it [1]. That gap matters because the protection the vaccine offers depends on completing every dose on time, and a child who misses the last one is left far short of the immunity the rollout was meant to deliver [1].

On X, the story tends to arrive as an unambiguous milestone: Africa's pioneering malaria-vaccine campaign, framed as a hard-won victory over one of the continent's deadliest childhood killers. The celebration is earned, but it emphasizes the science and the launch while skating past the harder, less shareable part of the story. AP's reporting from Cameroon points instead at the unglamorous middle of the pipeline, where the vaccine's promise is quietly eroded not by whether the shot works, but by whether an overstretched health system can bring the same child back, dose after dose, until the schedule is done [1]. For readers, the gap between the two frames is the difference between believing malaria is being beaten and understanding that the win is contingent on follow-through that Cameroon has not yet secured.

-- NORA WHITFIELD, London